WO2024095127A1

WO2024095127A1 - Solid state forms of tivozanib and process for preparation thereof

Info

Publication number: WO2024095127A1
Application number: PCT/IB2023/060916
Authority: WO
Inventors: Nikolina JANTON; Zvonimir PERKOVIC; Aleks LOGOŽAR; Robert OSTRIČKI
Original assignee: Pliva Hrvatska D.O.O.
Priority date: 2022-10-31
Filing date: 2023-10-30
Publication date: 2024-05-10

Abstract

The present disclosure encompasses solid state forms of Tivozanib, in embodiments crystalline polymorphs of Tivozanib, processes for preparation thereof, and pharmaceutical compositions thereof.

Description

SOLID STATE FORMS OF TIVOZANIB AND PROCESS FOR PREPARATION THEREOF

FIELD OF THE DISCLOSURE

[0001] The present disclosure encompasses solid state forms of Tivozanib, in embodiments crystalline polymorphs of Tivozanib, processes for preparation thereof, and pharmaceutical compositions thereof.

BACKGROUND OF THE DISCLOSURE

[0002] Tivozanib, l-[2-chloro-4-(6,7-dimethoxyquinolin-4-yl)oxyphenyl]-3-(5-methyl-l,2- oxazol-3-yl)urea, has the following chemical structure:

[0003] Tivozanib is a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor (TKI), and it is approved in the U.S. for the treatment of adult patients with relapsed or refractory advanced renal cell carcinoma (RCC) following two or more prior systemic therapies. It is marketed in the U.S. under the trade name FOTIVDA®.

[0004] The compound is described in U.S. Patent No. 6,821,987. Further, US Patent No. 7,166,722 discloses crystalline N-(2-chloro-4-(6,7-dimethoxy-4-quinolyl) oxyphenyl)-N'-(5- methyl-3-isoxazolyl)urea monohydrochloric acid salt monohydrate.

[0005] Polymorphism, the occurrence of different crystalline forms, is a property of some molecules and molecular complexes. A single molecule may give rise to a variety of polymorphs having distinct crystal structures and physical properties like melting point, thermal behaviors (e.g., measured by thermogravimetric analysis (“TGA”), or differential scanning calorimetry (“DSC”)), X-ray diffraction (XRD) pattern, infrared absorption fingerprint, and solid state (¹³C) NMR spectrum. One or more of these techniques may be used to distinguish different polymorphic forms of a compound.

[0006] Different salts and solid state forms (including solvated forms) of an active pharmaceutical ingredient may possess different properties. Such variations in the properties of different salts and solid state forms and solvates may provide a basis for improving formulation, for example, by facilitating better processing or handling characteristics, changing the dissolution profile in a favorable direction, or improving stability (polymorph as well as chemical stability) and shelf-life. These variations in the properties of different salts and solid state forms may also offer improvements to the final dosage form, for instance, if they serve to improve bioavailability. Different salts and solid state forms and solvates of an active pharmaceutical ingredient may also give rise to a variety of polymorphs or crystalline forms, which may in turn provide additional opportunities to assess variations in the properties and characteristics of a solid active pharmaceutical ingredient.

[0007] Discovering new solid state forms and solvates of a pharmaceutical product may yield materials having desirable processing properties, such as ease of handling, ease of processing, storage stability, and ease of purification or as desirable intermediate crystal forms that facilitate conversion to other polymorphic forms. New solid state forms of a pharmaceutically useful compound can also provide an opportunity to improve the performance characteristics of a pharmaceutical product. It enlarges the repertoire of materials that a formulation scientist has available for formulation optimization, for example by providing a product with different properties, including a different crystal habit, higher crystallinity, or polymorphic stability, which may offer better processing or handling characteristics, improved dissolution profile, or improved shelf-life (chemical/physical stability). For at least these reasons, there is a need for additional solid state forms (including solvated forms) of Tivozanib.

SUMMARY OF THE DISCLOSURE

[0008] The present disclosure provides crystalline polymorphs of Tivozanib, processes for preparation thereof, and pharmaceutical compositions thereof. These crystalline polymorphs can be used to prepare other solid state forms of Tivozanib, Tivozanib salts and their solid state forms.

[0009] The present disclosure also provides uses of the said solid state forms of API in the preparation of other solid state forms of Tivozanib or salts thereof. [0010] The present disclosure provides crystalline polymorphs of Tivozanib for use in medicine, including for the treatment of relapsed or refractory advanced renal cell carcinoma (RCC).

[0011] The present disclosure also encompasses the use of crystalline polymorphs of Tivozanib of the present disclosure for the preparation of pharmaceutical compositions and/or formulations.

[0012] In another aspect, the present disclosure provides pharmaceutical compositions comprising crystalline polymorphs of Tivozanib according to the present disclosure.

[0013] The present disclosure includes processes for preparing the above mentioned pharmaceutical compositions. The processes include combining any one or a combination of the crystalline polymorphs of Tivozanib with at least one pharmaceutically acceptable excipient.

[0014] The crystalline polymorph of Tivozanib as defined herein and the pharmaceutical compositions or formulations of the crystalline polymorph of Tivozanib may be used as medicaments, such as for the treatment of relapsed or refractory advanced renal cell carcinoma (RCC).

[0015] The present disclosure also provides methods of treating relapsed or refractory advanced renal cell carcinoma (RCC), by administering a therapeutically effective amount of any one or a combination of the crystalline polymorphs of Tivozanib of the present disclosure, or at least one of the above pharmaceutical compositions, to a subject suffering from relapsed or refractory advanced renal cell carcinoma (RCC), or otherwise in need of the treatment.

[0016] The present disclosure also provides uses of crystalline polymorphs of Tivozanib of the present disclosure, or at least one of the above pharmaceutical compositions, for the manufacture of medicaments for treating e.g. relapsed or refractory advanced renal cell carcinoma (RCC).

BRIEF DESCRIPTION OF THE DRAWINGS

[0017] Figure 1 shows a characteristic X-ray powder diffraction pattern (XRPD) of Tivozanib Form A;

[0018] Figure 2 shows a characteristic XRPD of a Tivozanib Form B;

[0019] Figure 3 shows a characteristic XRPD of a Tivozanib Form C;

[0020] Figure 4 shows a characteristic XRPD of a Tivozanib Form D;

[0021] Figure 5 shows a characteristic XRPD of a Tivozanib Form E; [0022] Figure 6 shows a characteristic XRPD of a Tivozanib Form F;

[0023] Figure 7 shows a characteristic XRPD of a Tivozanib Form G;

[0024] Figure 8 shows a characteristic XRPD of a Tivozanib Form H;

[0025] Figure 9 shows a characteristic XRPD of a Tivozanib HC1 Form IV;

[0026] Figure 10 shows a characteristic XRPD of a Tivozanib HC1 Form V;

[0027] Figure 11 shows a characteristic XRPD of a Tivozanib HC1 Form VI;

[0028] Figure 12 shows a characteristic XRPD of a Tivozanib HC1 Form VI (dried);

[0029] Figure 13 shows a characteristic XRPD of a Tivozanib Form I;

[0030] Figure 14 shows a characteristic XRPD of a Tivozanib Form O; and

[0031] Figure 15 shows a characteristic DSC thermogram of Tivozanib Form C.

DETAILED DESCRIPTION OF THE DISCLOSURE

[0032] The present disclosure encompasses solid state forms of Tivozanib, including crystalline polymorphs of Tivozanib, processes for preparation thereof, and pharmaceutical compositions thereof.

[0033] Solid state properties of Tivozanib and crystalline polymorphs thereof can be influenced by controlling the conditions under which Tivozanib and crystalline polymorphs thereof are obtained in solid form.

[0034] A solid state form (or polymorph) may be referred to herein as polymorphically pure or as substantially free of any other solid state (or polymorphic) forms. As used herein in this context, the expression "substantially free of any other forms" will be understood to mean that the solid state form contains about 20% (w/w) or less, about 10% (w/w) or less, about 5% (w/w) or less, about 2% (w/w) or less, about 1% (w/w) or less, or about 0% of any other forms of the subject compound as measured, for example, by XRPD. Thus, a crystalline polymorph of Tivozanib described herein as substantially free of any other solid state forms would be understood to contain greater than about 80% (w/w), greater than about 90% (w/w), greater than about 95% (w/w), greater than about 98% (w/w), greater than about 99% (w/w), or about 100% of the subject crystalline polymorph of Tivozanib. In some embodiments of the disclosure, the described crystalline polymorph of Tivozanib may contain from about 1% to about 20% (w/w), from about 5% to about 20% (w/w), or from about 5% to about 10% (w/w) of one or more other crystalline polymorph of the same Tivozanib. [0035] Depending on which other crystalline polymorphs a comparison is made, the crystalline polymorphs of Tivozanib of the present disclosure may have advantageous properties selected from at least one of the following: chemical purity, flowability, solubility, dissolution rate, morphology or crystal habit, stability, such as chemical stability as well as thermal and mechanical stability with respect to polymorphic conversion, stability towards dehydration and/or storage stability, low content of residual solvent, a lower degree of hygroscopicity, flowability, and advantageous processing and handling characteristics such as compressibility and bulk density.

[0036] A solid state form, such as a crystal form or an amorphous form, may be referred to herein as being characterized by graphical data “as depicted in” or “as substantially depicted in” a Figure. Such data include, for example, powder X-ray diffractograms and solid state NMR spectra. As is well-known in the art, the graphical data potentially provides additional technical information to further define the respective solid state form (a so-called “fingerprint”) which cannot necessarily be described by reference to numerical values or peak positions alone. In any event, the skilled person will understand that such graphical representations of data may be subject to small variations, e.g., in peak relative intensities and peak positions due to certain factors such as, but not limited to, variations in instrument response and variations in sample concentration and purity, which are well known to the skilled person. Nonetheless, the skilled person would readily be capable of comparing the graphical data in the Figures herein with graphical data generated for an unknown crystal form and confirm whether the two sets of graphical data are characterizing the same crystal form or two different crystal forms. A crystal form of Tivozanib referred to herein as being characterized by graphical data “as depicted in” or “as substantially depicted in” a Figure will thus be understood to include any crystal forms of Tivozanib characterized with the graphical data having such small variations, as are well known to the skilled person, in comparison with the Figure.

[0037] As used herein, and unless stated otherwise, the term “anhydrous” in relation to crystalline forms of Tivozanib, relates to a crystalline form of Tivozanib which does not include any crystalline water (or other solvents) in a defined, stoichiometric amount within the crystal. Moreover, an “anhydrous” form would generally not contain more than 1% (w/w), of either water or organic solvents as measured for example by TGA. [0038] The term "solvate," as used herein and unless indicated otherwise, refers to a crystal form that incorporates a solvent in the crystal structure. When the solvent is water, the solvate is often referred to as a "hydrate." The solvent in a solvate may be present in either a stoichiometric or in a non-stoichiometric amount.

[0039] As used herein, the term "isolated" in reference to crystalline polymorph of Tivozanib of the present disclosure corresponds to a crystalline polymorph of Tivozanib that is physically separated from the reaction mixture in which it is formed.

[0040] As used herein, unless stated otherwise, the XRPD measurements are taken using copper Ka radiation wavelength 1.5418 A. XRPD peaks reported herein are measured using CuK a radiation, X = 1.5418 A, typically at a temperature of 25 ± 3°C.

[0041] A thing, e.g., a reaction mixture, may be characterized herein as being at, or allowed to come to “room temperature” or “ambient temperature”, often abbreviated as “RT.” This means that the temperature of the thing is close to, or the same as, that of the space, e.g., the room or fume hood, in which the thing is located. Typically, room temperature is from about 20°C to about 30°C, or about 22°C to about 27°C, or about 25 °C.

[0042] The amount of solvent employed in a chemical process, e.g., a reaction or crystallization, may be referred to herein as a number of “volumes” or “vol” or “V.” For example, a material may be referred to as being suspended in 10 volumes (or 10 vol or 10V) of a solvent. In this context, this expression would be understood to mean milliliters of the solvent per gram of the material being suspended, such that suspending 5 grams of a material in 10 volumes of a solvent means that the solvent is used in an amount of 10 milliliters of the solvent per gram of the material that is being suspended or, in this example, 50 mL of the solvent. In another context, the term "v/v" may be used to indicate the number of volumes of a solvent that are added to a liquid mixture based on the volume of that mixture. For example, adding solvent X (1.5 v/v) to a 100 ml reaction mixture would indicate that 150 mL of solvent X was added. [0043] A process or step may be referred to herein as being carried out "overnight." This refers to a time interval, e.g., for the process or step, that spans the time during the night, when that process or step may not be actively observed. This time interval is from about 8 to about 20 hours, or about 10-18 hours, in some cases about 16 hours.

[0044] As used herein, the term “reduced pressure” refers to a pressure that is less than atmospheric pressure. For example, reduced pressure is about 10 mbar to about 50 mbar. [0045] As used herein and unless indicated otherwise, the term "ambient conditions" refer to atmospheric pressure and a temperature of 22-24°C.

[0046] The present disclosure includes a crystalline polymorph of Tivozanib, designated Form A. The crystalline Form A of Tivozanib may be characterized by data selected from one or more of the following: an X-ray powder diffraction pattern substantially as depicted in Figure 1; an X-ray powder diffraction pattern having peaks at 12.4, 13.3, 14.4, 25.0 and 26.1 degrees 2- theta ± 0.2 degrees 2-theta; and combinations of these data.

[0047] Crystalline Form A of Tivozanib may be further characterized by an X-ray powder diffraction pattern having peaks at 12.4, 13.3, 14.4, 25.0 and 26.1 degrees 2-theta ± 0.2 degrees 2-theta, and also having any one, two, three, four or five additional peaks selected from 11.0, 16.8, 18.5, 23.1 and 27.5 degrees 2-theta ± 0.2 degrees 2-theta.

[0048] In one embodiment of the present disclosure, crystalline Form A of Tivozanib is isolated.

[0049] Crystalline Form A of Tivozanib may be a hydrate form.

[0050] Crystalline Form A of Tivozanib may be characterized by each of the above characteristics alone/or by all possible combinations, e.g., an XRPD pattern having peaks at 12.4, 13.3, 14.4, 25.0 and 26.1 degrees 2-theta ± 0.2 degrees 2-theta; an XRPD pattern as depicted in Figure 1, and combinations thereof.

[0051] The present disclosure also includes a crystalline polymorph of Tivozanib, designated Form B. The crystalline Form B of Tivozanib may be characterized by data selected from one or more of the following: an X-ray powder diffraction pattern substantially as depicted in Figure 2; an X-ray powder diffraction pattern having peaks at 10.1, 12.7, 15.0, 19.0 and 21.0 degrees 2- theta ± 0.2 degrees 2-theta; and combinations of these data.

[0052] Crystalline Form B of Tivozanib may be further characterized by an X-ray powder diffraction pattern having peaks at 10.1, 12.7, 15.0, 19.0 and 21.0 degrees 2-theta ± 0.2 degrees 2-theta, and also having any one, two, three, or four additional peaks selected from 11.3, 15.8, 17.4 and 25.6 degrees 2-theta ± 0.2 degrees 2-theta.

[0053] In one embodiment of the present disclosure, crystalline Form B of Tivozanib is isolated.

[0054] Crystalline Form B of Tivozanib may be anhydrous. [0055] Crystalline Form B of Tivozanib may be characterized by each of the above characteristics alone/or by all possible combinations, e.g., an XRPD pattern having peaks at 10.1, 12.7, 15.0, 19.0 and 21.0 degrees 2-theta ± 0.2 degrees 2-theta; an XRPD pattern as depicted in Figure 2, and combinations thereof.

[0056] The present disclosure also includes a crystalline polymorph of Tivozanib, designated Form C. The crystalline Form C of Tivozanib may be characterized by data selected from one or more of the following: an X-ray powder diffraction pattern substantially as depicted in Figure 3; an X-ray powder diffraction pattern having peaks at 8.0, 14.9, 17.5, 24.2 and 25.6 degrees 2- theta ± 0.2 degrees 2-theta; and combinations of these data.

[0057] Crystalline Form C of Tivozanib may be further characterized by an X-ray powder diffraction pattern having peaks at 8.0, 14.9, 17.5, 24.2 and 25.6 degrees 2-theta ± 0.2 degrees 2- theta, and also having any one, two, three, four, or five additional peaks selected from 11.5, 13.1, 16.4, 20.6 and 22.1 degrees 2-theta ± 0.2 degrees 2-theta.

[0058] In one embodiment of the present disclosure, crystalline Form C of Tivozanib is isolated.

[0059] Crystalline Form C of Tivozanib may be anhydrous.

[0060] Crystalline Form C may be further characterized by a DSC thermogram having one or more of the following characteristics: an endothermic peak with an onset at about 233°C ± 3°C, an endothermic peak at about 235 °C ± 3°C, or an DSC thermogram substantially as depicted in Figure 15.

[0061] Crystalline Form C is stable at up to 100% relative humidity (RH) at room temperature for at least 7 days.

[0062] Crystalline Form C of Tivozanib may be characterized by each of the above characteristics alone/or by all possible combinations, e.g., an XRPD pattern having peaks at 8.0, 14.9, 17.5, 24.2 and 25.6 degrees 2-theta ± 0.2 degrees 2-theta; an XRPD pattern as depicted in Figure 3, and combinations thereof.

[0063] The present disclosure also includes a crystalline polymorph of Tivozanib, designated Form D. The crystalline Form D of Tivozanib may be characterized by data selected from one or more of the following: an X-ray powder diffraction pattern substantially as depicted in Figure 4; an X-ray powder diffraction pattern having peaks at 10.3, 10.6, 22.2, 23.4 and 25.0 degrees 2- theta ± 0.2 degrees 2-theta; and combinations of these data. [0064] Crystalline Form D of Tivozanib may be further characterized by an X-ray powder diffraction pattern having peaks at 10.3, 10.6, 22.2, 23.4 and 25.0 degrees 2-theta ± 0.2 degrees 2-theta, and also having any one, two, three, four, or five additional peaks selected from 8.6,

15.2, 18.5, 19.1 and 25.4 degrees 2-theta ± 0.2 degrees 2-theta.

[0065] In one embodiment of the present disclosure, crystalline Form D of Tivozanib is isolated.

[0066] Crystalline Form D of Tivozanib may be Ethanolate solvate.

[0067] Crystalline Form D of Tivozanib may be characterized by each of the above characteristics alone/or by all possible combinations, e.g., an XRPD pattern having peaks at

10.3, 10.6, 22.2, 23.4 and 25.0 degrees 2-theta ± 0.2 degrees 2-theta; an XRPD pattern as depicted in Figure 4, and combinations thereof.

[0068] The present disclosure also includes a crystalline polymorph of Tivozanib, designated Form E. The crystalline Form E of Tivozanib may be characterized by data selected from one or more of the following: an X-ray powder diffraction pattern substantially as depicted in Figure 5; an X-ray powder diffraction pattern having peaks at 10.7, 12.6, 14.1, 16.6 and 25.0 degrees 2- theta ± 0.2 degrees 2-theta; and combinations of these data.

[0069] Crystalline Form E of Tivozanib may be further characterized by an X-ray powder diffraction pattern having peaks at 10.7, 12.6, 14.1, 16.6 and 25.0 degrees 2-theta ± 0.2 degrees 2-theta, and also having any one, two, three, four, or five additional peaks selected from 10.2,

15.3, 20.2, 22.6 and 26.0 degrees 2-theta ± 0.2 degrees 2-theta.

[0070] In one embodiment of the present disclosure, crystalline Form E of Tivozanib is isolated.

[0071] Crystalline Form E of Tivozanib may be Acetone solvate.

[0072] Crystalline Form E of Tivozanib may be characterized by each of the above characteristics alone/or by all possible combinations, e.g., an XRPD pattern having peaks at 10.7, 12.6, 14.1, 16.6 and 25.0 degrees 2-theta ± 0.2 degrees 2-theta; an XRPD pattern as depicted in Figure 5, and combinations thereof.

[0073] The present disclosure also includes a crystalline polymorph of Tivozanib, designated Form F. The crystalline Form F of Tivozanib may be characterized by data selected from one or more of the following: an X-ray powder diffraction pattern substantially as depicted in Figure 6; an X-ray powder diffraction pattern having peaks at 9.9, 11.9, 14.8, 15.8 and 22.3 degrees 2- theta ± 0.2 degrees 2-theta; and combinations of these data.

[0074] Crystalline Form F of Tivozanib may be further characterized by an X-ray powder diffraction pattern having peaks at 9.9, 11.9, 14.8, 15.8 and 22.3 degrees 2-theta ± 0.2 degrees 2- theta, and also having any one, two, three, or four additional peaks selected from 20.2, 20.6, 23.8 and 27.7 degrees 2-theta ± 0.2 degrees 2-theta.

[0075] In one embodiment of the present disclosure, crystalline Form F of Tivozanib is isolated.

[0076] Crystalline Form F of Tivozanib may be a hemi-acetone solvate.

[0077] Crystalline Form F of Tivozanib may be characterized by each of the above characteristics alone/or by all possible combinations, e.g., an XRPD pattern having peaks at

9.9, 11.9, 14.8, 15.8 and 22.3 degrees 2-theta ± 0.2 degrees 2-theta; an XRPD pattern as depicted in Figure 6, and combinations thereof.

[0078] The present disclosure also includes a crystalline polymorph of Tivozanib, designated Form G. The crystalline Form G of Tivozanib may be characterized by data selected from one or more of the following: an X-ray powder diffraction pattern substantially as depicted in Figure 7; an X-ray powder diffraction pattern having peaks at 11.7, 17.4, 20.8, 24.1 and 28.6 degrees 2- theta ± 0.2 degrees 2-theta; and combinations of these data.

[0079] Crystalline Form G of Tivozanib may be further characterized by an X-ray powder diffraction pattern having peaks at 11.7, 17.4, 20.8, 24.1 and 28.6 degrees 2-theta ± 0.2 degrees 2-theta, and also having any one, two, three, four, or five additional peaks selected from 12.6, 15.4, 16.3, 21.3 and 26.9 degrees 2-theta ± 0.2 degrees 2-theta.

[0080] In one embodiment of the present disclosure, crystalline Form G of Tivozanib is isolated.

[0081] Crystalline Form G of Tivozanib may be a hydrate.

[0082] Crystalline Form G of Tivozanib may be characterized by each of the above characteristics alone/or by all possible combinations, e.g., an XRPD pattern having peaks at 11.7, 17.4, 20.8, 24.1 and 28.6 degrees 2-theta ± 0.2 degrees 2-theta; an XRPD pattern as depicted in Figure 7, and combinations thereof.

[0083] The present disclosure also includes a crystalline polymorph of Tivozanib, designated Form H. The crystalline Form H of Tivozanib may be characterized by data selected from one or more of the following: an X-ray powder diffraction pattern substantially as depicted in Figure 8; an X-ray powder diffraction pattern having peaks at 7.4, 12.0, 13.6, 20.0 and 25.6 degrees 2- theta ± 0.2 degrees 2-theta; and combinations of these data.

[0084] Crystalline Form H of Tivozanib may be further characterized by an X-ray powder diffraction pattern having peaks at 7.4, 12.0, 13.6, 20.0 and 25.6 degrees 2-theta ± 0.2 degrees 2- theta, and also having any one, two, three, four, or five additional peaks selected from 15.6, 16.1, 18.5, 21.6 and 24.4 degrees 2-theta ± 0.2 degrees 2-theta.

[0085] In one embodiment of the present disclosure, crystalline Form H of Tivozanib is isolated.

[0086] Crystalline Form H of Tivozanib may be a hydrate.

[0087] Crystalline Form H of Tivozanib may be characterized by each of the above characteristics alone/or by all possible combinations, e.g., an XRPD pattern having peaks at

7.4, 12.0, 13.6, 20.0 and 25.6 degrees 2-theta ± 0.2 degrees 2-theta; an XRPD pattern as depicted in Figure 8, and combinations thereof.

[0088] The present disclosure includes a crystalline polymorph of Tivozanib, designated Form J. The crystalline Form J of Tivozanib may be characterized by data selected from one or more of the following: an X-ray powder diffraction pattern substantially as depicted in Figure 13; an X-ray powder diffraction pattern having peaks at 4.4, 9.8, 15.9, 18.9 and 24.8 degrees 2-theta ± 0.2 degrees 2-theta; and combinations of these data.

[0089] Crystalline Form J of Tivozanib may be further characterized by an X-ray powder diffraction pattern having peaks at 4.4, 9.8, 15.9, 18.9 and 24.8 degrees 2-theta ± 0.2 degrees 2- theta, and also having any one, two, three, four or five additional peaks selected from 6.3, 13.0, 14.0, 14.8 and 26.8 degrees 2-theta ± 0.2 degrees 2-theta.

[0090] In one embodiment of the present disclosure, crystalline Form J of Tivozanib is isolated.

[0091] Crystalline Form J of Tivozanib may be an acetic acid solvate.

[0092] Crystalline Form J of Tivozanib may be characterized by each of the above characteristics alone/or by all possible combinations, e.g., an XRPD pattern having peaks at

4.4, 9.8, 15.9, 18.9 and 24.8 degrees 2-theta ± 0.2 degrees 2-theta; an XRPD pattern as depicted in Figure 13, and combinations thereof. [0093] The present disclosure includes a crystalline polymorph of Tivozanib, designated Form O. The crystalline Form O of Tivozanib may be characterized by data selected from one or more of the following: an X-ray powder diffraction pattern substantially as depicted in Figure 14; an X-ray powder diffraction pattern having peaks at 9.0, 13.6, 15.1, 17.5 and 24.1 degrees 2- theta ± 0.2 degrees 2-theta; and combinations of these data.

[0094] Crystalline Form O of Tivozanib may be further characterized by an X-ray powder diffraction pattern having peaks at 9.0, 13.6, 15.1, 17.5 and 24.1 degrees 2-theta ± 0.2 degrees 2- theta, and also having any one, two, three, four or five additional peaks selected from 12.2, 19.8, 22.4, 25.0 and 26.2 degrees 2-theta ± 0.2 degrees 2-theta.

[0095] In one embodiment of the present disclosure, crystalline Form O of Tivozanib is isolated.

[0096] Crystalline Form O of Tivozanib may be a monoacetic acid solvate.

[0097] Crystalline Form O of Tivozanib may be characterized by each of the above characteristics alone/or by all possible combinations, e.g., an XRPD pattern having peaks at 9.0, 13.6, 15.1, 17.5 and 24.1 degrees 2-theta ± 0.2 degrees 2-theta; an XRPD pattern as depicted in Figure 14, and combinations thereof.

[0098] The present disclosure also includes a crystalline polymorph of Tivozanib HC1, designated Form IV. The crystalline Form IV of Tivozanib HC1 may be characterized by data selected from one or more of the following: an X-ray powder diffraction pattern substantially as depicted in Figure 9; an X-ray powder diffraction pattern having peaks at 11.9, 16.4, 17.5, 18.1 and 28.2 degrees 2-theta ± 0.2 degrees 2-theta; and combinations of these data.

[0099] Crystalline Form IV of Tivozanib HC1 may be further characterized by an X-ray powder diffraction pattern having peaks at 11.9, 16.4, 17.5, 18.1 and 28.2 degrees 2-theta ± 0.2 degrees 2-theta, and also having any one, two, three, four, or five additional peaks selected from 15.9, 19.2, 23.2, 24.2 and 25.1 degrees 2-theta ± 0.2 degrees 2-theta.

[00100] In one embodiment of the present disclosure, crystalline Form IV of Tivozanib HC1 is isolated.

[00101] Crystalline Form IV of Tivozanib HC1 may be anhydrous.

[00102] Crystalline Form IV of Tivozanib HC1 may be characterized by each of the above characteristics alone/or by all possible combinations, e.g., an XRPD pattern having peaks at 11.9, 16.4, 17.5, 18.1 and 28.2 degrees 2-theta ± 0.2 degrees 2-theta; an XRPD patern as depicted in Figure 9, and combinations thereof.

[00103] The present disclosure also includes a crystalline polymorph of Tivozanib HC1, designated Form V. The crystalline Form V of Tivozanib HC1 may be characterized by data selected from one or more of the following: an X-ray powder diffraction pattern substantially as depicted in Figure 10; an X-ray powder diffraction pattern having peaks at 6.9, 7.3, 11.9, 14.6 and 24.9 degrees 2-theta ± 0.2 degrees 2-theta; and combinations of these data.

[00104] Crystalline Form V of Tivozanib HC1 may be further characterized by an X-ray powder diffraction pattern having peaks at 6.9, 7.3, 11.9, 14.6 and 24.9 degrees 2-theta ± 0.2 degrees 2-theta, and also having any one, two, three, four, or five additional peaks selected from 15.7, 19.4, 21.9, 23.6 and 27.8 degrees 2-theta ± 0.2 degrees 2-theta.

[00105] In one embodiment of the present disclosure, crystalline Form V of Tivozanib HC1 is isolated.

[00106] Crystalline Form V of Tivozanib HC1 may be a hemi-DMF solvate.

[00107] Crystalline Form V of Tivozanib HC1 may be characterized by each of the above characteristics alone/or by all possible combinations, e.g., an XRPD patern having peaks at

6.9, 7.3, 11.9, 14.6 and 24.9 degrees 2-theta ± 0.2 degrees 2-theta; an XRPD pattern as depicted in Figure 10, and combinations thereof.

[00108] The present disclosure also includes a crystalline polymorph of Tivozanib HC1, designated Form VI. The crystalline Form VI of Tivozanib HC1 may be characterized by data selected from one or more of the following: an X-ray powder diffraction pattern substantially as depicted in Figure 11 or Figure 12; an X-ray powder diffraction patern having peaks at 4.7, 7.4, 9.4, 12.3 and 18.2 degrees 2-theta ± 0.2 degrees 2-theta; and combinations of these data.

[00109] Crystalline Form VI of Tivozanib HC1 may be further characterized by an X-ray powder diffraction pattern having peaks at 4.7, 7.4, 9.4, 12.3 and 18.2 degrees 2-theta ± 0.2 degrees 2-theta, and also having any one, two, or three additional peaks selected from 19.5, 19.8 and 22.2 degrees 2-theta ± 0.2 degrees 2-theta.

[00110] In one embodiment of the present disclosure, crystalline Form VI of Tivozanib HC1 is isolated.

[00111] Crystalline Form VI of Tivozanib HC1 may be characterized by each of the above characteristics alone/or by all possible combinations, e.g., an XRPD patern having peaks at 4.7, 7.4, 9.4, 12.3 and 18.2 degrees 2-theta ± 0.2 degrees 2-theta; an XRPD patern as depicted in Figure 11 or Figure 12, and combinations thereof.

[00112] The above crystalline polymorphs can be used to prepare other crystalline polymorphs of Tivozanib, Tivozanib salts and their solid state forms.

[00113] The present disclosure encompasses a process for preparing other solid state forms of Tivozanib, Tivozanib salts and their solid state forms thereof. The process includes preparing any one of the solid state forms of Tivozanib by the processes of the present disclosure, and converting that form to another form of Tivozanib or to a Tivozanib salt. The conversion can be done, for example, by a process including reacting any one or a combination of the above forms of Tivozanib with an appropriate acid, to obtain the corresponding Tivozanib salt.

[00114] The present disclosure provides the above described crystalline polymorphs of Tivozanib for use in the preparation of pharmaceutical compositions comprising Tivozanib and/or crystalline polymorphs thereof.

[00115] The present disclosure also encompasses the use of crystalline polymorphs of Tivozanib of the present disclosure for the preparation of pharmaceutical compositions of crystalline polymorph Tivozanib and/or crystalline polymorphs thereof.

[00116] The present disclosure includes processes for preparing the above mentioned pharmaceutical compositions. The processes include combining any one or a combination of the crystalline polymorphs of Tivozanib of the present disclosure with at least one pharmaceutically acceptable excipient.

[00117] Pharmaceutical combinations or formulations of the present disclosure contain any one or a combination of the solid state forms of Tivozanib of the present disclosure. In addition to the active ingredient, the pharmaceutical formulations of the present disclosure can contain one or more excipients. Excipients are added to the formulation for a variety of purposes.

[00118] Diluents increase the bulk of a solid pharmaceutical composition, and can make a pharmaceutical dosage form containing the composition easier for the patient and caregiver to handle. Diluents for solid compositions include, for example, microcrystalline cellulose (e.g. Avicel®), microfine cellulose, lactose, starch, pregelatinized starch, calcium carbonate, calcium sulfate, sugar, dextrates, dextrin, dextrose, dibasic calcium phosphate dihydrate, tribasic calcium phosphate, kaolin, magnesium carbonate, magnesium oxide, maltodextrin, mannitol, polymethacrylates (e.g. Eudragit®), potassium chloride, powdered cellulose, sodium chloride, sorbitol, and talc.

[00119] Solid pharmaceutical compositions that are compacted into a dosage form, such as a tablet, can include excipients whose functions include helping to bind the active ingredient and other excipients together after compression. Binders for solid pharmaceutical compositions include acacia, alginic acid, carbomer (e.g. carbopol), carboxymethylcellulose sodium, dextrin, ethyl cellulose, gelatin, guar gum, hydrogenated vegetable oil, hydroxy ethyl cellulose, hydroxypropyl cellulose (e.g. Klucel®), hydroxypropyl methyl cellulose (e.g. Methocel®), liquid glucose, magnesium aluminum silicate, maltodextrin, methylcellulose, polymethacrylates, povidone (e.g. Kollidon®, Plasdone®), pregelatinized starch, sodium alginate, and starch.

[00120] The dissolution rate of a compacted solid pharmaceutical composition in the patient's stomach can be increased by the addition of a disintegrant to the composition. Disintegrants include alginic acid, carboxymethylcellulose calcium, carboxymethylcellulose sodium (e.g. Ac- Di-Sol®, Primellose®), colloidal silicon dioxide, croscarmellose sodium, crospovidone (e.g. Kollidon®, Polyplasdone®), guar gum, magnesium aluminum silicate, methyl cellulose, microcrystalline cellulose, polacrilin potassium, powdered cellulose, pregelatinized starch, sodium alginate, sodium starch glycolate (e.g. Explotab®), and starch.

[00121] Glidants can be added to improve the flowability of a non-compacted solid composition and to improve the accuracy of dosing. Excipients that can function as glidants include colloidal silicon dioxide, magnesium trisilicate, powdered cellulose, starch, talc, and tribasic calcium phosphate.

[00122] When a dosage form such as a tablet is made by the compaction of a powdered composition, the composition is subjected to pressure from a punch and dye. Some excipients and active ingredients have a tendency to adhere to the surfaces of the punch and dye, which can cause the product to have pitting and other surface irregularities. A lubricant can be added to the composition to reduce adhesion and ease the release of the product from the dye. Lubricants include magnesium stearate, calcium stearate, glyceryl monostearate, glyceryl palmitostearate, hydrogenated castor oil, hydrogenated vegetable oil, mineral oil, polyethylene glycol, sodium benzoate, sodium lauryl sulfate, sodium stearyl fumarate, stearic acid, talc, and zinc stearate. [00123] Flavoring agents and flavor enhancers make the dosage form more palatable to the patient. Common flavoring agents and flavor enhancers for pharmaceutical products that can be included in the composition of the present disclosure include maltol, vanillin, ethyl vanillin, menthol, citric acid, fumaric acid, ethyl maltol, and tartaric acid.

[00124] Solid and liquid compositions can also be dyed using any pharmaceutically acceptable colorant to improve their appearance and/or facilitate patient identification of the product and unit dosage level.

[00125] In liquid pharmaceutical compositions of the present invention, Tivozanib and any other solid excipients can be dissolved or suspended in a liquid carrier such as water, vegetable oil, alcohol, polyethylene glycol, propylene glycol, or glycerin.

[00126] Liquid pharmaceutical compositions can contain emulsifying agents to disperse uniformly throughout the composition an active ingredient or other excipient that is not soluble in the liquid carrier. Emulsifying agents that can be useful in liquid compositions of the present invention include, for example, gelatin, egg yolk, casein, cholesterol, acacia, tragacanth, chondrus, pectin, methyl cellulose, carbomer, cetostearyl alcohol, and cetyl alcohol.

[00127] Liquid pharmaceutical compositions of the present invention can also contain a viscosity enhancing agent to improve the mouth-feel of the product and/or coat the lining of the gastrointestinal tract. Such agents include acacia, alginic acid bentonite, carbomer, carboxymethylcellulose calcium or sodium, cetostearyl alcohol, methyl cellulose, ethylcellulose, gelatin guar gum, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methyl cellulose, maltodextrin, polyvinyl alcohol, povidone, propylene carbonate, propylene glycol alginate, sodium alginate, sodium starch glycolate, starch tragacanth, xanthan gum and combinations thereof.

[00128] Sweetening agents such as sorbitol, saccharin, sodium saccharin, sucrose, aspartame, fructose, mannitol, and invert sugar can be added to improve the taste.

[00129] Preservatives and chelating agents such as alcohol, sodium benzoate, butylated hydroxyl toluene, butylated hydroxyanisole, and ethylenediamine tetraacetic acid can be added at levels safe for ingestion to improve storage stability.

[00130] According to the present disclosure, a liquid composition can also contain a buffer such as gluconic acid, lactic acid, citric acid, or acetic acid, sodium gluconate, sodium lactate, sodium citrate, or sodium acetate. Selection of excipients and the amounts used can be readily determined by the formulation scientist based upon experience and consideration of standard procedures and reference works in the field. [00131] The solid compositions of the present disclosure include powders, granulates, aggregates, and compacted compositions. The dosages include dosages suitable for oral, buccal, rectal, parenteral (including subcutaneous, intramuscular, and intravenous), inhalant, and ophthalmic administration. Although the most suitable administration in any given case will depend on the nature and severity of the condition being treated, in embodiments the route of administration is oral. The dosages can be conveniently presented in unit dosage form and prepared by any of the methods well-known in the pharmaceutical arts.

[00132] Dosage forms include solid dosage forms like tablets, powders, capsules, suppositories, sachets, troches, and lozenges, as well as liquid syrups, suspensions, and elixirs. [00133] The dosage form of the present disclosure can be a capsule containing the composition, such as a powdered or granulated solid composition of the disclosure, within either a hard or soft shell. The shell can be made from gelatin and optionally contain a plasticizer such as glycerin and/or sorbitol, an opacifying agent and/or colorant.

[00134] The active ingredient and excipients can be formulated into compositions and dosage forms according to methods known in the art.

[00135] A composition for tableting or capsule filling can be prepared by wet granulation. In wet granulation, some or all of the active ingredients and excipients in powder form are blended and then further mixed in the presence of a liquid, typically water, that causes the powders to clump into granules. The granulate is screened and/or milled, dried, and then screened and/or milled to the desired particle size. The granulate can then be tableted, or other excipients can be added prior to tableting, such as a glidant and/or a lubricant.

[00136] A tableting composition can be prepared conventionally by dry blending. For example, the blended composition of the actives and excipients can be compacted into a slug or a sheet and then comminuted into compacted granules. The compacted granules can subsequently be compressed into a tablet.

[00137] As an alternative to dry granulation, a blended composition can be compressed directly into a compacted dosage form using direct compression techniques. Direct compression produces a more uniform tablet without granules. Excipients that are particularly well suited for direct compression tableting include microcrystalline cellulose, spray dried lactose, dicalcium phosphate dihydrate, and colloidal silica. The proper use of these and other excipients in direct compression tableting is known to those in the art with experience and skill in particular formulation challenges of direct compression tableting.

[00138] A capsule filling of the present disclosure can include any of the aforementioned blends and granulates that were described with reference to tableting, but they are not subjected to a final tableting step.

[00139] A pharmaceutical formulation of Tivozanib can be administered. Tivozanib may be formulated for administration to a mammal, in embodiments to a human, by injection. Tivozanib can be formulated, for example, as a viscous liquid solution or suspension, such as a clear solution, for injection. The formulation can contain one or more solvents. A suitable solvent can be selected by considering the solvent's physical and chemical stability at various pH levels, viscosity (which would allow for syringeability), fluidity, boiling point, miscibility, and purity. Suitable solvents include alcohol USP, benzyl alcohol NF, benzyl benzoate USP, and Castor oil USP. Additional substances can be added to the formulation such as buffers, solubilizers, and antioxidants, among others. Ansel et al., Pharmaceutical Dosage Forms and Drug Delivery Systems, 7th ed.

[00140] The crystalline polymorphs of Tivozanib and the pharmaceutical compositions and/or formulations of Tivozanib of the present disclosure can be used as medicaments, in embodiments in the treatment of relapsed or refractory advanced renal cell carcinoma (RCC).

[00141] The present disclosure also provides methods of treating relapsed or refractory advanced renal cell carcinoma (RCC) by administering a therapeutically effective amount of any one or a combination of the crystalline polymorphs of Tivozanib of the present disclosure, or at least one of the above pharmaceutical compositions and/or formulations, to a subject in need of the treatment.

[00142] Having thus described the disclosure with reference to particular preferred embodiments and illustrative examples, those in the art can appreciate modifications to the disclosure as described and illustrated that do not depart from the spirit and scope of the disclosure as disclosed in the specification. The Examples are set forth to aid in understanding the disclosure but are not intended to, and should not be construed to limit its scope in any way.

Powder X-ray Diffraction method

[00143] Sample after being powdered in a mortar and pestle is applied directly on a silicon plate holder. The X-ray powder diffraction pattern was measured with Philips X'Pert PRO X-ray powder diffractometer, equipped with Cu irradiation source =1.54184 A (Angstrom), X’Celerator (2.022° 20) detector. Scanning parameters: angle range: 3-40 deg., step size 0.0167, time per step 37 s, continuous scan.

Differential scanning calorimetry ("DSC")

[00144] DSC analysis was performed on instrument QI 000 MDSC TA with a heating rate of 10°C/min and under nitrogen flow of 50 mL/min. Standard aluminum closed pan (with hole) was used, sample mass was 1-5 mg.

[00145] Modulated DSC was performed on instrument Q1000 MDSC TA with a heating rate of 2°C/min and modulate temperature amplitude 0.32°C every 60 sec. Analysis was done under nitrogen flow of 50 mL/min. Standard aluminum closed pan was used, sample mass was 1-5 mg.

EXAMPLES

Preparation of starting materials

[00146] Tivozanib can be prepared according to methods known from the literature, for example according to U.S. Patent No. 6,821,987. Tivozanib hydrochloride, Form I can be prepared according to U.S. Patent No. 7,166,722.

Example 1: Preparation of Tivozanib Form A

[00147] Tivozanib (0.05 grams) was dissolved in methanol (6 mL) at 64°C. Obtained solution was cooled to RT, crystallization flask was sealed and left to crystallize at RT. After 1 day, obtained solid was isolated by vacuum filtration over the black ribbon and analyzed by XRPD. Tivozanib Form A was obtained.

Example 2: Preparation of Tivozanib Form B

[00148] Tivozanib Form A (0.1 grams) was dried at 100°C and 10 mbar in vacuum oven for 12 hours. Obtained solid was analyzed by XRPD. Tivozanib Form B was obtained.

Example 3: Preparation of Tivozanib Form C

[00149] Tivozanib (0.05 grams) was dissolved in acetone (4 mL) at room temperature (25°C). Crystallization flask was sealed and left to crystallize at room conditions. After 5 days, obtained solid was isolated by vacuum filtration over the black ribbon and analyzed by XRPD. Tivozanib Form C was obtained. Example 4: Preparation of Tivozanib Form D

[00150] Tivozanib Form A (0.5 grams) was suspended in ethanol (5 mL) at 5-10°C and stirred for 2 hours. The mixture was filtered over filter paper with 0.45 pm pores and analyzed by XRPD. Tivozanib Form D was obtained.

Example 5: Preparation of Tivozanib Form E

[00151] Tivozanib hydrochloride Form I (2.0 grams) was suspended in acetone : water (30 mL, 4 : 1). NaOH aqueous solution (IM, 4.2 mL) was added drop-wise to the base suspension at RT. The suspension was stirred for 12 hours, filtered over the black ribbon under vacuum and analyzed by XRPD. Tivozanib Form E was obtained.

Example 6: Preparation of Tivozanib Form F

[00152] Tivozanib Form E (1.0 gram) was dried at 50°C and 10 mbar for 6 hours. The obtained solid was analyzed by XRPD. Tivozanib Form F was obtained.

Example 7: Preparation of Tivozanib Form G

[00153] Tivozanib hydrochloride Form I (0.5 grams) was suspended in methyl ethyl ketone : water (10 mL, 20 : 1). NaOH aqueous solution (IM, 1.1 mL) was added drop-wise to the base suspension at RT. Suspension was stirred for 12 hours and filtered over the black ribbon under vacuum. The obtained solid was analyzed by XRPD. Tivozanib Form F was obtained.

Example 8: Preparation of Tivozanib Form H

[00154] Tivozanib hydrochloride Form I (0.5 grams) was suspended in methyl /.s -butyl ketone : water (10 mL, 20 : 1). NaOH aqueous solution (IM, 1.1 mL) was added dropwise to the base suspension at RT. The suspension was stirred for 12 hours and filtered over the black ribbon under vacuum. The obtained solid was analyzed by XRPD. Tivozanib Form H was obtained.

Example 9: Preparation of Tivozanib HC1 Form IV

[00155] Tivozanib hydrochloride Form I (0.1 gram) was placed in ‘Anton Paar TTK 450’ chamber on Philips X'Pert PRO X-ray powder diffractometer. The sample was heated up to 160°C by heating rate 10°C/min and analyzed by XRPD. Tivozanib hydrochloride Form IV was obtained.

Example 10: Preparation of Tivozanib HC1 Form V

[00156] Tivozanib hydrochloride Form I (4 grams) was suspended in dimethylformamide (3 mL) at RT and stirred for 3 days. The obtained solid was isolated by vacuum filtration over the black ribbon filter paper and analyzed by XRPD Tivozanib hydrochloride Form V was obtained. Example 11: Preparation of Tivozanib HC1 Form VI

[00157] Tivozanib hydrochloride Form 1 (1 gram) was suspended in methanol (70 mL) at RT and stirred for 6 hours. The suspension was filtered over filter paper with <5 = 0.45 pm pores under vacuum. The obtained solid was dried at 100°C and 10 mbar for 6 hours and the sample was analyzed by XRPD. Tivozanib HC1 Form VI was obtained.

Example 12: Preparation of Tivozanib HC1 Form VI - dried

[00158] Tivozanib hydrochloride Form VI (0.1 grams) was placed in ‘Anton Paar TTK 450’ chamber on Philips X'Pert PRO X-ray powder diffractometer. The sample was heated up to 170°C by heating rate 10°C/min and analyzed by XRPD Tivozanib hydrochloride form VI (dried) was obtained.

Example 13; Preparation of Tivozanib Form J

[00159] Crude Tivozanib (1.0 gram) was dissolved in acetic acid (8.0 mL) at room temperature and heated up to 55-60°C. Crystallization occurred at about 55°C. Acetic acid was added (8.0 mL) and stirred for 1 hour at 55-60°C. Heating was discontinued, and the solution was cooled to room temperature and stirred for 2 hours. The obtained solid was isolated by vacuum filtration, washed with acetic acid (2 x 1 mL) and dried at 50°C and 10 mbar for 6 hours. According to XRPD analysis Tivozanib form J was obtained.

Example 14; Preparation of Tivozanib Form J

[00160] Crude Tivozanib (10.4 grams) was suspended in acetic acid (0.17 L) at room temperature and heated up to 65-70°C until complete dissolution was achieved. Solution was cooled to 55-60°C, seeded with Tivozanib form J (0.052 g) and stirred for 30 minutes. Suspension was further cooled to room temperature and stirred for 2 hours. Obtained solid was isolated by vacuum filtration, washed with acetic acid (2 x 21 mL) and dried at room conditions over night. According to XRPD analysis Tivozanib form J was obtained.

Example 15; Preparation of Tivozanib Form O

[00161] Tivozanib form J (23.8 grams) was suspended in 96% ethanol / acetic acid (9:1, 0.1 L) at 60-65°C and stirred for 2 hours. Heating was discontinued, suspension was cooled to room temperature for 1 hour and stirred at room temperature for additional 2 hours. The obtained solid was isolated by vacuum filtration, washed with 96% ethanol / acetic acid (9:1, 2 x 21 mL) and dried at 60°C and 10 mbar for 6 hours. According to XRPD analysis Tivozanib form O was obtained. Example 16: Preparation of Tivozanib Form C

[00162] Step 1 : 3-Amino-5-methylisoxazole (14.2 grams) and pyridine (61.0 grams) were dissolved in acetonitrile (132 mL) at room temperature. The solution was cooled at 0°C and phenyl chloroformate (22.7 grams) was added drop wise to the solution with temperature maintained below 7°C. Reaction mixture was heated to 20-25°C and stirred for 1 hour.

[00163] Step 2: 2-chloro-4-((6,7-dimethoxyquinolin-4-yl)oxy)aniline (30.0 grams) was dissolved in acetonitrile (180 mL) at 73-75°C. The prepared solution from Step 1 was added drop wise for 2 hours at 73-75°C. The reaction mixture was stirred for 10 hours at 73-75°C, cooled to 20-25°C and oxolane (150 mL) was added drop wise for 30 minutes. After that, water (300 ml) was added drop wise for 30 minutes. pH was adjusted between 7.5-8.5 with 3M NaOH. The reaction mixture was heated at 60°C, stirred for 2 hours, cooled to 20-25°C and stirred for 2 hours. Obtained solid was isolated by vacuum filtration, washed two times with THF : water (1: 1, 2x60 mL) and with water (30 mL). The crystals were dried in a vacuum oven at 50°C and 10 mbar until constant mass. Tivozanib Form C was obtained.

Example 17: Preparation of Tivozanib Form J

[00164] Tivozanib Form C (85.0 grams) was dissolved in acetic acid (1360 mL) at 65-70° C. the solution was cooled to 54-56° C, seeded with Tivozanib Form J (0.43 grams) and stirred for 1 hour. The suspension was cooled to 20-25°C, stirred for 2 hours and filtered. The obtained solid was washed two times with ethanoic acid (2x170 mL) and dried at 50°C and 10 mbar for 16 hours. Tivozanib Form J was obtained. 1

Claims

CLAIMS:

1. Crystalline Form C of Tivozanib, which is characterized by data selected from one or more of the following: i. an XRPD pattern having peaks at 8.0, 14.9, 17.5, 24.2 and 25.6 degrees 2-theta ± 0.2 degrees 2-theta; ii. an XRPD pattern as depicted in Figure 3.

2. A crystalline form of Tivozanib according to claim 1, which is characterized by an XRPD pattern having peaks at 8.0, 14.9, 17.5, 24.2 and 25.6 degrees 2-theta ± 0.2 degrees 2-theta, and also having one, two, three, four or five additional peaks selected from 11.5, 13.1, 16.4, 20.6 and 22.1 degrees 2-theta ± 0.2 degrees 2-theta..

3. A pharmaceutical composition comprising a crystalline form according to any one of claims lor 2.

4. Use of a crystalline form according to any one of claims 1 or 2 in the preparation of a pharmaceutical composition and/or formulation.

5. A pharmaceutical formulation comprising a crystalline form according to any one of claims lor 2 or a pharmaceutical composition of claim 3, and at least one pharmaceutically acceptable excipient.

6. A crystalline form according to any one of claims 1 or 2, a pharmaceutical composition according to claim 3, or a pharmaceutical formulation according to claim 4, for use as a medicament.

7. A crystalline form according to any one of claims 1 or 2, a pharmaceutical composition according to claim 3, or a pharmaceutical formulation according to claim 4, for use in the treatment of adult patients with relapsed or refractory advanced renal cell carcinoma (RCC).

8. Use of a crystalline form according to any one of claims 1 or 2, a pharmaceutical composition according to claim 3, or a pharmaceutical formulation according to claim 4, for the manufacture of a medicament for treatment of adult patients with relapsed or refractory advanced renal cell carcinoma (RCC). A process for preparing a solid state form of Tivozanib, or a Tivozanib salt, or a solid state form of a Tivozanib salt, comprising preparing a crystalline form of Tivozanib according to any one of claims 1 or 2 and converting it to another solid state form of Tivozanib, a Tivozanib salt or a solid state form of a Tivozanib salt. Use of a crystalline form according to any one of claims 1 or 2 for the preparation of another crystalline form of Tivozanib, or a Tivozanib salt, or a solid state form of a Tivozanib salt.